Dermaliq appoints Gordon Dow, PharmD, Michael Kuligowski, MD, PhD, R. Todd Plott, MD and Xavier Yon to its Dermatology Scientific and Medical Advisory Board
Dermaliq Therapeutics, Inc. (Dermaliq), a private biopharmaceutical company with therapeutic focus on dermatology, today announces the formation of a Scientific and Medical Advisory Board composed of internationally recognized experts in dermatology, Gordon Dow (San Francisco, US,), Xavier Yon (Paris, France), Michael Kuligowski, MD, PhD (Chads Ford, US) and R. Todd Plott, MD (Dallas/Fort Worth, US). The Advisory Board is composed of key clinical investigators and industry veterans in the field who support and guide the development of unique topical medications based on our water-free hyliQ technology platform. Mr. Dow has been named Chairman of the Advisory board.
Frank Loescher, PhD, CEO Dermaliq, said, “we are pleased to welcome four highly respected members to our Scientific and Medical Advisory Board as we now advance three programs into the clinic: DLQ01 (Androgenetic Alopecia), DLQ02 (Psoriasis) and DLQ03 (Bacterial Skin and Soft Tissue Infections). The vast clinical and research expertise in dermatology of this group is invaluable for shaping Dermaliq’s current and future product development strategy. The board and the entire team look forward to working closely with them.”
Gordon Dow, PharmD (Chairman) is former CEO, Founder & CTO of Dow Pharmaceutical Sciences Inc, a dermatology specialty company which developed topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies. Dow was acquired by Valeant, now Bausch Health, for US$ 400 million in 2008. Dr. Dow is a recognized expert in topical product formulations and a leading innovator for a number of approved and successful dermatology products.
Dr. Dow said, “Dermaliq’s hyliQ platform is a step forward in topical formulations and has the potential of being the first real game-changer in dermal delivery since decades.”
Michael Kuligowski, MD, PhD, MBA, is Vice President, Global Product Development, Dermatology at Thermo Fisher. He is an experienced industry dermatologist with 12 years of clinical practice in dermatology, primarily in an academic setting, with strong scientific and clinical background. His pharmaceutical experience spans 25+ years in companies of various sizes In Europe and in North America. Among other successes, Dr. Kuligowski played a key role in the development and approval of the first topical JAK-inhibitor at Incyte where he served as Executive Medical Director, Inflammation & Autoimmunity.
Dr. Kuligowski stated “Better and more effective topical products are needed to serve the needs of patients and practicing physicians. Innovation in the topical space is needed to develop formulations which can provide safe, enhanced drug delivery, especially for substances which are difficult to solubilize and maintain stability. Dermaliq’s novel drug delivery has the promise to address these needs”.
R. Todd Plott, MD, is a board-certified dermatologist in the Dallas/Fort Worth area and Chief Medical Officer of Epiphany Dermatology with 30 years of experience in clinical dermatology. Before entering private practice, Dr Plott spent 16 years in the pharmaceutical industry developing several dermatology drugs widely prescribed by dermatologists, his most notable invention is Solodyn™.
“Treatment of dermatology diseases remains unsatisfactory for many patients. Dermaliq’s lead developments in psoriasis and skin infections offer an intriguing proposition if confirmed in the upcoming clinical trials” said Dr. Plott.
Xavier Yon, is former CEO of Galderma and a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as Chief Executive Officer of Galderma for 17 years. During his time at Galderma Mr. Yon built the company from its initial spin out from Alcon to be a world leader in ethical dermatology. Mr. Yon holds a number of active board and advisor roles. He holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris.
“Dermaliq offers the opportunity to establish a highly attractive product portfolio based on its hyliQ platform, with increased patient compliance and greater patient satisfaction due to the unique platform-related cosmetic properties”, said Mr. Yon.
Dermaliq Therapeutics, Inc. is a private company founded in 2021 through a spin off from Novaliq to reimagine topical dermatology. The Company is incorporated in Wilmington (DE), USA under Delaware law.
Dermaliq’s mission is to develop a new generation of superior topical therapeutics and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability, stability and cosmetic acceptability.
Dermaliq secured USD 15 million in a series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration9.8.2022 06:00:00 CEST | Press release
Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, has announced that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by BSI certification agency as complying with the European In-vitro Diagnostic Regulation (IVDR), EU 2017/746. This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union. The IVDR’s extensive requirements were adopted by the European Parliament in 2017 and must now be implemented by May 26, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005159/en/ FIVE MINUTES TO SAVE LIVES - Immediate clinical decision-making at your fingertips (Photo: Business Wire) IVDR becomes mandatory as of May 26, 2022. There are also transitional rules that will allow well-established instruments that have not been IVDR certified, but that entered the EU before, to still be sold until 202
A Digital Twin of Kabuki Actor Shido Nakamura Created with NTT’s Another Me Technology Debuts at “Cho Kabuki 2022 Powered by NTT”9.8.2022 05:03:00 CEST | Press release
NTT Corporation (President: Akira Shimada, “NTT”) and Shochiku Co., Ltd. (President & CEO: Junichi Sakamoto) have announced "Cho Kabuki 2022 Powered by NTT" sponsored by Shochiku, with the first act starring Shido Nakamura's digital twin, “Shido Twin.” The debut of Shido Twin showcases NTT’s research and development of a computer that reproduces people as digital twins and is the first step in the social implementation of this new technology. We hope you will come and witness the birth of Shido Nakamura reproduced as a digital twin. Created in collaboration with Shochiku Co., Ltd., the Shido Twin autonomously reproduces the gestures of Shido Nakamura, who plays the leading role in Cho-kabuki, using the body motion generation technology of Another Me. Another Me is a technology born out of NTT’s Digital Twin Computing1 concept. With Another Me, we aim to allow individuals to create an “alternative self” in the digital space, dramatically increasing the opportunities to flourish and grow
IFF Reports Second Quarter 2022 Results8.8.2022 22:21:00 CEST | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the second quarter ended June 30, 2022. Management Commentary "We continued to execute on our near-term operational priorities to achieve strong top and bottom-line results in the second quarter," said IFF CEO Frank Clyburn. "Our teams have acted with urgency to implement necessary pricing actions in collaboration with our customers and delivered productivity benefits that offset on-going inflationary pressures. Going forward, we are preparing for more uncertain market conditions, yet remain confident in delivering our full year financial objectives. At the same time, we are advancing our strategic efforts, deploying innovation, refining our portfolio and strengthening our culture to deliver strong value creation for all our stakeholders. Reflecting our confidence, we are pleased to announce that we are raising our quarterly dividend. This marks thirteen years of consecutive dividend increases and unders
Waldom Electronics Announces New Advisory Board8.8.2022 20:30:00 CEST | Press release
Waldom Electronics is excited to announce the launch of its Advisory Board comprised of recognized leaders who will bring their knowledge and experience to the company. The Advisory Board will work closely with Don Akery, Waldom’s Chief Executive Officer, to help maximize performance with special focus on long term strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220805005440/en/ Kevin Rock (Photo: Business Wire) Waldom’s Chairman, Jamil Nizam stated, “In order to build on our significant growth over the last several years, I have been working diligently to create a world-class Advisory Board. I am thrilled to have assembled this board of exceptional individuals who will bring their skills, experience and objectivity to help Waldom realize its goals, vision and mission.” Waldom welcomes the following members to its Advisory Board: - Kevin Rock, Former President of TE Connectivity’s Industrial Solutions Segment with o
Sermo Barometer Reveals Growing Concern Among Global Physicians Regarding Monkeypox8.8.2022 16:00:00 CEST | Press release
With the spread of monkeypox on the rise and the World Health Organization (WHO) declaring a global health emergency, findings from a recent survey conducted by Sermo, a physician-first online community and leader in global HCP insights, show there is high concern about public misinformation spreading. The survey also found that while 71% of respondents would recommend vaccination as a preventative measure to a patient who was concerned about contracting monkeypox, 65% of doctors say their country does not have enough vaccines. The barometer survey included 1,011 physician respondents from 20 countries, with key findings including: Concerns About Misinformation Seventy-eight percent of physician respondents are concerned about the spread of monkeypox misinformation and 60% are concerned that monkeypox is being categorized incorrectly as a sexually transmitted disease, such as syphilis or HPV. Based on lessons from the COVID-19 pandemic, 36% feel public health authorities should priorit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom